NCT00094029Approved For Marketing不适用
A Treatment Protocol For Patients With Gastrointestinal Stromal Tumor Who Are Ineligible For Participation In Other SU011248 Protocols And Are Refractory To Or Intolerant Of Imatinib Mesylate
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 发起方
- Pfizer
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to permit access to SU011248 for treatment use by patients with GIST given the following conditions: a) patients undergo screening, but are not eligible for participation in ongoing clinical studies such as A6181004; AND b) patients have GIST which standard treatments have not been able to control with acceptable toxicity AND c) patients have the potential to derive clinical benefit from treatment with SU011248.
详细描述
Given that an Expanded Access study does not meet the definition of a controlled clinical investigation, and as such, is not considered an applicable drug clinical trial per NIH, Basic Results for such studies are not required to be reported. Protocol A6181036 has been identified as an Expanded Access trial, and has been registered to ClinicalTrials.gov, however Basic Results will not be posted.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven Gastrointestinal Stomal Tumor (GIST) that is not amenable to standard therapy
- •Undergone screening and found to be ineligible for participation in ongoing SU011248 clinical studies
- •Patient judged to have potential to derive clinical benefit from SU011248 treatment by the treating physician
- •Failed prior treatment with imatinib mesylate, defined as either progression of disease or significant toxicity during treatment with imatinib mesylate that precluded further treatment
- •Male or Female, 18 years or older
- •Resolution of all acute toxicities of prior therapies
- •Adequate organ function
排除标准
- •Symptomatic congestive heart failure, myocardial infarction, or coronary artery bypass graft in the last 6 months, or ongoing severe or unstable angina or any unstable arrhythmia requiring medication
- •Symptomatic central nervous system metastases
- •Serious acute or chronic illness
- •Current treatment on another clinical trial
- •Pregnant or breastfeeding.
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
A Treatment Protocol for Patients with Gastrointestinal Stromal Tumor who are Ineligible for Participation in Other SU011248 Protocols AND are Refractory to or Intolerant of Imatinib Mesylate.Gastro-intestinal Stromal TumorsMedDRA version: 14.1Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2004-001860-27-ITPFIZER1,098
进行中（未招募）
不适用
A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATEPatients with Gastrointestinal Stromal Tumor who are Refractory to Standard Therapy and May Derive Benefit for Treatment with SU011248MedDRA version: 7.1Level: LLYClassification code 10062427EUCTR2004-001860-27-FIPfizer Oy1,500
进行中（未招募）
1 期
A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATEPatients with Gastrointestinal Stromal Tumor who are Refractory to Standard Therapy and May Derive Benefit for Treatment with SU011248MedDRA version: 7.1 Level: LLY Classification code 10062427EUCTR2004-001860-27-GBPfizer Limited1,500
进行中（未招募）
不适用
A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATEEUCTR2004-001860-27-GRPfizer Hellas A.E.500
进行中（未招募）
不适用
A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATEPatients with Gastrointestinal Stromal Tumor who are Refractory to Standard Therapy and May Derive Benefit for Treatment with SU011248MedDRA version: 7.1Level: LLYClassification code 10062427EUCTR2004-001860-27-HUPfizer Kft.500